- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
R&D
Lilly wins further delay in sales of Strattera copies
August 26, 2010
Bloomberg NewsStrattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
MoreLilly gains panel's backing to expand Cymbalta use
August 19, 2010
Bloomberg NewsOutside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
MoreLilly Alzheimer's drug prospect only the latest to fail
August 18, 2010
Bloomberg NewsA dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
MoreLilly's Cymbalta helps chronic pain in U.S. review
August 17, 2010
Bloomberg NewsApproval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta's
annual sales.
MoreLilly braces for plunge in profits
August 14, 2010
J.K. WallIndianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of
loss of revenue that it's hard to picture what the company will look like in five years.
MoreContract pharmaceutical research firm expands to New Jersey
July 10, 2010
J.K. WallConcentrics grows in spite of recession as drug companies look for help to handle patent expirations
MoreLilly's Lechleiter: No change in plans
July 7, 2010
J.K. WallThe global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.
MoreMarcadia enlists Lilly to help develop new diabetes drug
June 28, 2010
J.K. WallThe two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
MoreQ&A
June 23, 2010
J.K. WallDavid Stocum is the director of the Center for Regenerative Biology and Medicine at the IUPUI School of Science.
He and his team are studying how amphibians regenerate parts of their bodies to see if there are ways to induce humans to
regenerate tissue that is lost or damaged. The center has about 20 researchers and funding of about $14 million to fuel its
quest.
MoreResearch reforms will force Lilly, others to test how drugs stack up
June 12, 2010
J.K. WallThe federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical
treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness
research could threaten their sales.
MoreClosing of Purdue's Chao Center is setback for BioCrossroads
May 1, 2010
J.K. WallThe university is hoping to find a private company to take over the 5-year-old facility, which formulated and manufactured
small batches of drugs used in clinical trials.
MoreHarlan Labs names new CEO
April 23, 2010
IBJ StaffThe Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
MoreLilly sues to block generic of Adcirca lung treatment
March 17, 2010
Bloomberg NewsNetherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
MoreLilly pays $50M-plus for rights to testosterone lotion
March 16, 2010
Bloomberg NewsIndianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
MoreLilly, Merck, Pfizer starting research center
February 23, 2010
Associated PressThree major U.S. drugmakers said they have formed a not-for-profit company in Asia to focus on cancer research and treatments.
MoreTeva gets European OK to sell generic of Lilly's Evista
February 19, 2010
Bloomberg NewsEvista generated $1.03 billion in sales last year, of which $348.1 million came outside the United States.
MorePfizer's Viagra patent partially rejected in Lilly fight
February 16, 2010
Bloomberg NewsThe patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn't different
enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against
Eli Lilly and Co. over its rival Cialis drug.
MoreCity of Greenwood might fund launch of insulin maker
January 30, 2010
Kathleen McLaughlinGreenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin,
a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal
that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
MoreLilly looks to autoimmune drugs
January 27, 2010
J.K. WallTwo local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune
diseases: The costs of treating them are growing twice as fast as the prescription drug market.
MoreLilly launching new venture capital fund
December 10, 2009
J.K. WallThe fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly's
drug pipeline.
MoreLilly extends research pact with India firm
December 1, 2009
IBJ StaffJubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
MoreAarden Pharmaceuticals chose Indianapolis over San Diego for headquarters
November 14, 2009
IBJ StaffThanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided
locating here would give Aarden a better chance of success.
MoreLilly needs to sell more Effient before Zyprexa loses patent protection
October 24, 2009
J.K. WallSales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The
blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for
the quarter.
MoreEli Lilly CEO banking on new drug pipeline
October 22, 2009
Associated PressCEO John Lechleiter says Lilly's pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He's betting there will be a fourth.
MoreLilly, GE announce cancer diagnostic breakthrough
October 21, 2009
J.K. WallEli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the
size and cost of its clinical trials.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
I'm sure there are others, but his name automatically came to my mind
Houdini
magician on the court
STEVE MARTIN - funny magic
It has to be Houdini!